Evidence from increasingly recognised favourable subgroups (CUP-CCP, CUP-LCP, CUP-RCC), as well as rarer emerging subgroups (TTF1-negative NSCLC, iCCA) suggest maximising diagnostic capability to identify TOO offers patients a potential survival advantage. This evidence concerns the gene TTF1 and non-small cell lung carcinoma.